Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
12d
Gilead Sciences Inc (GILD) reports robust financial performance with significant sales growth in key therapeutic areas and ...
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...
DelveInsight's Antibody-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...
Gilead Sciences (NASDAQ:GILD), a biopharmaceutical powerhouse known for its dominant HIV franchise, finds itself at a critical juncture as it navigates challenges in oncology while seeking to ...
Erratum: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, ...
On October 8, 2024, PhRMA held a media briefing to address growing concerns over the Inflation Reduction Act (IRA) and its effects on the biopharmaceutical industry, Medicare Part D beneficiaries, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback